Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2015 1
2017 2
2020 2
2021 2
2022 2
2023 1
2024 2
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K. McGarry A, et al. Lancet Neurol. 2024 Jan;23(1):37-45. doi: 10.1016/S1474-4422(23)00378-2. Lancet Neurol. 2024. PMID: 38101901 Clinical Trial.
BACKGROUND: Converging lines of evidence suggest that microglia are relevant to Parkinson's disease pathogenesis, justifying exploration of therapeutic agents thought to attenuate pathogenic microglial function. We sought to test the safety and efficacy of NL …
BACKGROUND: Converging lines of evidence suggest that microglia are relevant to Parkinson's disease pathogenesis, justifying exploration of …
Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review.
Hung SW, Zhang R, Tan Z, Chung JPW, Zhang T, Wang CC. Hung SW, et al. Med Res Rev. 2021 Jul;41(4):2489-2564. doi: 10.1002/med.21802. Epub 2021 May 5. Med Res Rev. 2021. PMID: 33948974 Free PMC article.
N-acetyl cysteine, curcumin, and ginsenoside exert antioxidant and anti-inflammatory effects via radical scavenging activity. Natural products have high efficacy with minimal side effects; for example, resveratrol and epigallocatechin gallate have mult …
N-acetyl cysteine, curcumin, and ginsenoside exert antioxidant and anti-inflammatory effects via radical scavenging activit …
Safety, efficacy and anti-inflammatory activity of rho iso-alpha-acids from hops.
Hall AJ, Babish JG, Darland GK, Carroll BJ, Konda VR, Lerman RH, Bland JS, Tripp ML. Hall AJ, et al. Phytochemistry. 2008 May;69(7):1534-47. doi: 10.1016/j.phytochem.2008.02.001. Epub 2008 Mar 20. Phytochemistry. 2008. PMID: 18358504 Clinical Trial.
A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficacy and safety. ...Cardiovascular safety was addressed by PGI-M measurements where RIAA (1000 mg) did not reduce PGI-M or af …
A defined mixture of rho iso-alpha-acids (RIAA), a modified hop extract, was evaluated for anti-inflammatory efficac …
Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease.
Vernero M, Bezzio C, Ribaldone DG, Costa S, Scalvini D, Tribocco E, Manes G, Saibeni S. Vernero M, et al. J Clin Med. 2023 Oct 29;12(21):6839. doi: 10.3390/jcm12216839. J Clin Med. 2023. PMID: 37959304 Free PMC article.
(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory bowel disease (IBD). To date, there is little real-world data about the use of GP2017 in IBD patients. ...The clinical activity was ev …
(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory b …
Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.
Cudkowicz M, Drory VE, Chio A, Lunetta C, Shoesmith C, van Eijk RPA, Salomon-Zimri S, Shtossel D, Kerem N, Shapira G, Shomron N, Russek-Blum N, Tracik F, Rosenfeld J, Shefner J. Cudkowicz M, et al. JAMA Neurol. 2026 May 1;83(5):471-480. doi: 10.1001/jamaneurol.2026.0230. JAMA Neurol. 2026. PMID: 41837970 Free PMC article. Clinical Trial.
PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammation, iron homeostasis, and dysregulated microRNAs. OBJECTIVE: To evaluate the safety, tolerability, and potential efficacy of Pr …
PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammatio …
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC).
Noviello D, Fries W, Orlando A, Conforti FS, Bezzio C, Castiglione F, Fantini MC, Savarino EV, Festa S, Ribaldone DG, Mocci G, Grossi L, Viganò C, Imperatore N, Ceccarelli L, Gabrielli AMC, Scardino G, Saibeni S, Balestrieri P, Principi M, Campigotto M, Gravina AG, Spagnuolo R, Scaldaferri F, Neri B, Sario AD, Baldoni M, Mitri RD, Tettoni E, Calderone S, Armuzzi A, Macaluso FS, Vecchi M, Ventimiglia M, Caprioli F; VE2TO-UC study group. Noviello D, et al. Dig Liver Dis. 2025 Jul;57(7):1419-1427. doi: 10.1016/j.dld.2025.04.025. Epub 2025 May 6. Dig Liver Dis. 2025. PMID: 40335332
BACKGROUND AND AIMS: Drug positioning in ulcerative colitis (UC) patients refractory to anti-tumor necrosis factor (TNF) is still debated. In a nationwide multicentre observational cohort, we aimed to compare the real-life effectiveness and safety of tofacitinib and …
BACKGROUND AND AIMS: Drug positioning in ulcerative colitis (UC) patients refractory to anti-tumor necrosis factor (TNF) is still deb …
Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
Matsuoka K, Hirai F, Watanabe K, Hokari R, Kobayashi T, Saruta M, Nakase H, Suzuki T, Yamazaki G, Hibi T, Watanabe M, Hisamatsu T. Matsuoka K, et al. J Gastroenterol. 2025 Dec;60(12):1523-1534. doi: 10.1007/s00535-025-02299-9. Epub 2025 Sep 22. J Gastroenterol. 2025. PMID: 40982097 Free PMC article. Clinical Trial.
BACKGROUND: Carotegrast methyl is approved for treating patients with moderately active ulcerative colitis with inadequate response to 5-aminosalicylic acid agents. However, real-world evidence to guide optimal use is limited. ...CONCLUSIONS: Carotegrast methyl appe …
BACKGROUND: Carotegrast methyl is approved for treating patients with moderately active ulcerative colitis with inadequate response t …
Efficacy and safety of Shi's cervical manipulation versus diclofenac for patients with acute and subacute neck pain: a multicenter clinical randomized trial.
Mingcai Z, Xun L, Guoqing DU, Congying L, Weian Y, Wei LI, Jiayu Y, Bo C, Xiaoyue YU, Yizhe X, Enyu J, Ningyang G, Sumin J, Zhenqiu XU, Xiang W, Hongsheng Z, Yufeng WU. Mingcai Z, et al. J Tradit Chin Med. 2025 Dec;45(6):1385-1394. doi: 10.19852/j.cnki.jtcm.2025.06.016. J Tradit Chin Med. 2025. PMID: 41376230 Free PMC article. Clinical Trial.
OBJECTIVE: To confirm the effectiveness and safety of Shi's manipulation in treating acute and subacute neck pain patients. METHODS: This multicenter, positive controlled, randomized clinical trial has trial and control groups. ...Secondary secondary outcome index include, …
OBJECTIVE: To confirm the effectiveness and safety of Shi's manipulation in treating acute and subacute neck pain patients. METHODS: …
Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis: Results From a Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study.
Karłowicz K, Lewandowski K, Kaniewska MA, Głuszek-Osuch M, Domżał-Magrowska D, Talar-Wojnarowska R, Skonieczna-Żydecka K, Marlicz W, Małecka-Wojciesko E, Rydzewska G. Karłowicz K, et al. Med Sci Monit. 2025 Dec 21;31:e948912. doi: 10.12659/MSM.948912. Med Sci Monit. 2025. PMID: 41422374 Free PMC article. Clinical Trial.
BACKGROUND Microencapsulated sodium butyrate (MSB) is a colon-targeted form of butyric acid with anti-inflammatory and mucosal healing properties. This study evaluated its efficacy and safety as add-on therapy for inducing remission in patients with mi …
BACKGROUND Microencapsulated sodium butyrate (MSB) is a colon-targeted form of butyric acid with anti-inflammatory and mucosal …
Anti-melanogenic effects of hot-water extracts from Torreya nucifera via MAPKs and cAMP signaling pathway on B16F10 cells.
Ko JH, Lee N, Kang HK, Kim BS, Lee JN, Hyun CG. Ko JH, et al. Pharmazie. 2020 Nov 1;75(11):565-570. doi: 10.1691/ph.2020.0522. Pharmazie. 2020. PMID: 33239130 Free article.
Torreya nucifera is an evergreen tree in the family Taxaceae, the seeds, leaves, and stems of which have long been used as edible products and herbal medicines in Korea. Previous studies of biological activity have shown that T. nucifera has antioxidant and anti- …
Torreya nucifera is an evergreen tree in the family Taxaceae, the seeds, leaves, and stems of which have long been used as edible products a …
18 results